PIK3CA and non-small cell lung carcinoma: For instance, in gefitinib-resistant NSCLC cells A431, the loss of expression of insulin-like growth factor binding proteins (IGFBP) 3 and 4 leads to activation of the IGF-1R/PI3K/AKT pathway.